Additional file 2: Supplemental materials and methods, and supplemental figure S1-S9.Figure S1. Numbers of m6A-regulated lncRNAs across tissues. Figure S2. Numbers of m6A-regulated TE lncRNAs across tissues in four data resources. Figure S3. Distribution of odds ratios for comparison between TE lncRNAs and non-TE lncRNAs across tissues in four data resources. Figure S4. Number of m6A peaks correlated with TE lncRNAs in four resources. Figure S5.Co-expression between m6A regulators and m6A-modified TE lncRNAs. A, River plot showing the expression correlation between m6A modified TE lncRNAs and m6A regulators. B, Bar plots showing the number of m6A regulators correlated with each m6A modified TE lncRNA. Color indicated the different data resources. C-E, Scatter plots showing the correlation between the expression of lncRNAs and m6A regulators. C for PVT1 and YTHDF2; D for SOX2-OT and HNRNPA2B1; E for KCNK15-AS1 and ALKBH5. Figure S6. Numbers of TE lncRNAs correlated with m6A regulators. Figure S7. Number of m6A modified TE lncRNAs across cancer types. Figure S8. GSEA for m6A modified lncRNAs in HCC, LGG and GBM. A, F11-AS1 in HCC; B, LINC01018 in HCC; C, MIR325HG in LGG, D, MIR325HG in GBM. Figure S9. GSEA figures for m6A-modified lncRNAs in HCC, LGG and GBM. A, F11-AS1 enriched in DNA repair pathway in HCC; B, LINC01018 enriched in DNA repair pathway in HCC; C, MIR325HG enriched in EMT pathway in LGG, D, MIR325HG enriched in EMT pathway in GBM.
